Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs
- Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs
- 이현범; Jose I. Juncosa; Richard B. Silverman
- ornithine aminotransferase (OAT); gamma-aminobutyric acid aminotransferase(GABA-AT); hepatocellular carcinoma (HCC); irreversible enzyme inhibition
- Issue Date
- Medicinal research reviews
- VOL 35, NO 2-305
- Ornithine aminotransferase (OAT) and γ -aminobutyric acid aminotransferase (GABA-AT) are classified under the same evolutionary subgroup and share a large portion of structural, functional, and mechanistic features. Therefore, it is not surprising that many molecules that bind to GABA-AT also bind well to OAT. Unlike GABA-AT, OAT had not been viewed as a potential therapeutic target until recently; consequently, the number of therapeutically viable molecules that target OAT is very limited. In this review the two enzymes are compared with respect to their active-site structures, catalytic and inactivation mechanisms, and selective inhibitors. Insight is offered that could aid in the design and development of new selective inhibitors of OAT for the treatment of cancer.
- Appears in Collections:
- KIST Publication > ETC
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.